Median Technologies announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its eyonis® LCS device. This technology is designed to assist in the detection and diagnosis of lung cancer using artificial intelligence (AI).
The eyonis® LCS system represents a novel approach to lung cancer screening by integrating AI algorithms to analyze imaging data. The device aims to support healthcare professionals in identifying lung cancer at earlier stages.
**Why this matters**
Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Early and accurate detection is critical for improving patient outcomes. The FDA clearance of an AI-based screening tool like eyonis® LCS could enhance diagnostic accuracy and efficiency in clinical settings.
Source: NewsData